

# 5

## Summary & Closing

# R&D PIPELINE OVERVIEW AND MILESTONES

Platform	Product candidate	Preclinical	Phase I	Phase II	Phase III	Last event	Next expected event	
ONCOS oncolytic adenovirus	ONCOS-102	Mesothelioma Comb. w/ pemetrexed/cisplatin <sup>1</sup>					Phase Ib safety lead-in cohort, incl. immune activation and ORR data (6 pts)	<b>1H 2020</b> Randomized ORR data 30 pts
		Melanoma Comb. w/KEYTRUDA®					ORR and immune activation (6 pts), 1/6 CR	<b>1H 2019</b> ORR and immune data first cohort (n=8)
		Peritoneal cancers <sup>2,3</sup> Partner: Ludwig, CRI & AZ Comb. w/IMFINZI®					First dose escalation cohort safety review (4 pts)	<i>Update by partner, expected 2019</i>
		Prostate <sup>3</sup> Partner: Sotio Comb. w/DCVAC					First patient dosed	<i>Update by partner, expected 2019</i>
	Next-gen ONCOS	3 viruses undisclosed					Virus construct cloning and <i>in vitro</i> validation	<b>2H 2019</b> Target disclosure and <i>in vivo</i> data
TG neo- antigen cancer vaccine	TG01	Pancreatic cancer Comb. w/gemcitabine					mOS 33.4 months Demonstrated mutant RAS- specific immune activation	TBD
	TG02	Colorectal cancer Proof-of-mechanism Comb. w/KEYTRUDA®					First safety review, incl. immune activation data (3 pts)	<b>1H 2019</b> Immune activation and mechanistic data
	TG02	CPI synergy TG + PD-1						<b>1H 2019</b> TG02 + PD-1 combination <i>in vivo</i> data

<sup>1</sup> Current standard of care chemotherapy for patients with unresectable malignant pleural mesothelioma

<sup>2</sup> Patients with advanced peritoneal disease, who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer

<sup>3</sup> Partner sponsored trials

■ Ongoing partner sponsored trials

# ONCOS-102 phase I/II development strategy

## COVERING THE BASES

### Delivery route

---

#### Local

Intra-tumoral injection



---

#### Compartmental

Intra-peritoneal infusion



---

#### Systemic

Intra-venous infusion

*TBD*  
*future*

### Combination therapy

---

#### Chemotherapy

Cytostatics, SoC



---

#### Checkpoint inhibitor

PD-1 & PD-L1 blockade




---

#### Cell therapy

DC vaccine





targovax